Literature DB >> 25227185

Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms.

Jarmila Kissova1, Alena Bulikova, Petra Ovesna, Ludmila Bourkova, Miroslav Penka.   

Abstract

BCR/ABL-negative myeloproliferative neoplasms (MPNs) are considered to be acquired thrombophilic conditions. Persistently enhanced platelet activation has been described in polycythaemia vera and essential thrombocythaemia (ET), and shown to contribute to a higher risk of arterial and venous thrombotic complications. Recent studies have shown that mean platelet volume (MPV) and immature platelet fraction (IPF) can serve as useful markers of platelet activation and increased risk of thrombosis. The aim of the present study was to investigate the relationship between these parameters and thrombotic events in BCR/ABL-negative MPN. MPV values in patients with BCR/ABL-negative MPN were significantly higher than MPV values of healthy individuals (P < 0.001). No significant difference in MPV or IPF was observed between groups of patients with and without thrombotic complications (P = 0.441; P = 0.110); the difference in IPF values was close to the significance level for patients with ET (P = 0.073). Higher values of IPF were more frequently detected in patients with JAK2 V617F positivity (P = 0.030). These patients had higher MPV more frequently than others, and this difference was close to the significance level (P = 0.056). Further studies should validate the use of platelet parameters to identify patients at high risk.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25227185     DOI: 10.1007/s12185-014-1673-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  38 in total

1.  Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera.

Authors:  A Falanga; M Marchetti; V Evangelista; A Vignoli; M Licini; M Balicco; S Manarini; G Finazzi; C Cerletti; T Barbui
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

Review 2.  Platelet activation: assessment and quantification.

Authors:  S Kamath; A D Blann; G Y Lip
Journal:  Eur Heart J       Date:  2001-09       Impact factor: 29.983

3.  Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo.

Authors:  R Landolfi; G Ciabattoni; P Patrignani; M A Castellana; E Pogliani; B Bizzi; C Patrono
Journal:  Blood       Date:  1992-10-15       Impact factor: 22.113

4.  Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera.

Authors:  Anna Falanga; Marina Marchetti; Alfonso Vignoli; Donatella Balducci; Tiziano Barbui
Journal:  Exp Hematol       Date:  2005-05       Impact factor: 3.084

5.  Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia.

Authors:  Issa J Dahabreh; Katerina Zoi; Stavroula Giannouli; Christine Zoi; Dimitrios Loukopoulos; Michael Voulgarelis
Journal:  Leuk Res       Date:  2008-07-15       Impact factor: 3.156

6.  Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia.

Authors:  Eduardo Arellano-Rodrigo; Alberto Alvarez-Larrán; Juan Carlos Reverter; Neus Villamor; Josep Maria Jou; Francisco Cervantes
Journal:  Platelets       Date:  2011-11-07       Impact factor: 3.862

Review 7.  Thrombotic disease in the myeloproliferative neoplasms.

Authors:  Anna Falanga; Marina Marchetti
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

8.  Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.

Authors:  Eduardo Arellano-Rodrigo; Alberto Alvarez-Larrán; Juan-Carlos Reverter; Dolors Colomer; Neus Villamor; Beatriz Bellosillo; Francisco Cervantes
Journal:  Am J Hematol       Date:  2009-02       Impact factor: 10.047

9.  Immature platelets in patients with acute coronary syndromes.

Authors:  Erik Lerkevang Grove; Anne-Mette Hvas; Steen Dalby Kristensen
Journal:  Thromb Haemost       Date:  2009-01       Impact factor: 5.249

10.  Relationships between platelet counts, platelet volumes and reticulated platelets in patients with ITP: evidence for significant platelet count inaccuracies with conventional instrument methods.

Authors:  M Diquattro; F Gagliano; G M Calabrò; M Tommasi; C S Scott; G Mancuso; B Palma; I Menozzi
Journal:  Int J Lab Hematol       Date:  2008-01-07       Impact factor: 2.877

View more
  8 in total

Review 1.  Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.

Authors:  Somedeb Ball; Kyaw Zin Thein; Abhishek Maiti; Kenneth Nugent
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

2.  Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis.

Authors:  Marko Lucijanic; Zdravko Mitrovic; David Cicic; Zeljko Prka; Vlatko Pejsa; Ana Livun; Tajana Stoos-Veic; Zeljko Romic; Marcela Zivkovic; Iva Lucijanic; Zrinka Fabris; Rajko Kusec
Journal:  Int J Hematol       Date:  2017-10-11       Impact factor: 2.490

3.  Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.

Authors:  Mónica Mejía-Ochoa; Paola Andrea Acevedo Toro; Jaiberth Antonio Cardona-Arias
Journal:  BMC Cancer       Date:  2019-06-17       Impact factor: 4.430

4.  Anagrelide Modulates Proplatelet Formation Resulting in Decreased Number and Increased Size of Platelets.

Authors:  Naohiro Miyashita; Masahiro Onozawa; Shota Yokoyama; Daisuke Hidaka; Koji Hayasaka; Shinji Kunishima; Takanori Teshima
Journal:  Hemasphere       Date:  2019-08-07

5.  Platelets contribute to disease severity in COVID-19.

Authors:  Tessa J Barrett; Seda Bilaloglu; Macintosh Cornwell; Hannah M Burgess; Vitor W Virginio; Kamelia Drenkova; Homam Ibrahim; Eugene Yuriditsky; Yin Aphinyanaphongs; Mark Lifshitz; Feng Xia Liang; Julie Alejo; Grace Smith; Stefania Pittaluga; Amy V Rapkiewicz; Jun Wang; Camelia Iancu-Rubin; Ian Mohr; Kelly Ruggles; Kenneth A Stapleford; Judith Hochman; Jeffrey S Berger
Journal:  J Thromb Haemost       Date:  2021-09-29       Impact factor: 5.824

6.  Cytoreductive treatment and association with platelet function and maturity in patients with essential thrombocythaemia.

Authors:  Oliver Buchhave Pedersen; Erik Lerkevang Grove; Leonardo Pasalic; Hans Beier Ommen; Steen Dalby Kristensen; Anne-Mette Hvas
Journal:  Br J Haematol       Date:  2022-06-08       Impact factor: 8.615

7.  Combination of platelet count and mean platelet volume (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patients.

Authors:  Fan Zhang; Zhaoli Chen; Pan Wang; Xueda Hu; Yibo Gao; Jie He
Journal:  Tumour Biol       Date:  2016-01-16

Review 8.  The Provocative Roles of Platelets in Liver Disease and Cancer.

Authors:  Preeti Kanikarla Marie; Natalie W Fowlkes; Vahid Afshar-Kharghan; Stephanie L Martch; Alexey Sorokin; John Paul Shen; Van K Morris; Arvind Dasari; Nancy You; Anil K Sood; Michael J Overman; Scott Kopetz; David George Menter
Journal:  Front Oncol       Date:  2021-07-21       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.